Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.51 |
| ▸ | PDE4A | P27815 | 9/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2465157 | 1.00 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL537211 | 0.93 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL694925 | 0.93 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL8279948 | 0.92 | PDE4B (0.50) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL1582796 | 0.91 | TP53 (0.50) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL537220 | 0.91 | TP53 (0.50) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL694628 | 0.91 | PDE4B (0.49) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL537241 | 0.91 | PDE4B (0.49) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL2466089 | 0.90 | PDE4B (0.60) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL2466090 | 0.90 | PDE4B (0.60) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | disclosed |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | AMGEN INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-2583098-B1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORP (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2017070291-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170087129-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | NEW YORK UNIVERSITY | 2017-03-30 | — | — | US | disclosed |
| US-20170087129-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | NEW YORK UNIVERSITY | 2017-03-30 | — | — | US | disclosed |
| US-20160289188-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION | 2016-10-06 | — | — | US | disclosed |
| US-20160289188-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION | 2016-10-06 | — | — | US | disclosed |
| US-9408831-B2 | Methods for treating respiratory viral infection | CELGENE CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408831-B2 | Methods for treating respiratory viral infection | CELGENE CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| US-20090148388-A1 | Isoindoline Compounds and Methods of Making and Using the Same | CELGENE CORPORATION | 2009-06-11 | — | — | US | disclosed |
| US-7495112-B2 | Isoindoline compounds and methods of making and using the same | CELGENE CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495112-B2 | Isoindoline compounds and methods of making and using the same | CELGENE CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070244183-A1 | Isoindoline compounds and methods of making and using the same | CELGENE CORPORATION | 2007-10-18 | — | — | US | disclosed |
| US-20070244183-A1 | Isoindoline compounds and methods of making and using the same | CELGENE CORPORATION | 2007-10-18 | — | — | US | disclosed |
| US-20070190070-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | CELGENE CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070190070-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | CELGENE CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-7244759-B2 | Isoindoline compounds and methods of making and using the same | CELGENE CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244759-B2 | Isoindoline compounds and methods of making and using the same | CELGENE CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2005046592-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS | CELGENE CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190070-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | IL2, IL6, BDNF | PDE4B 1668/4885PDE4C 1599/4885PDE4A 1445/4885 |
| US-20160289188-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4C 3/4885PDE4A 1/4885 |
| US-20170087129-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | PDE4A, PDE4B, PDE3B | PDE4B 2/4885PDE4C 4/4885PDE4A 1/4885 |
| US-20090148388-A1 | Isoindoline Compounds and Methods of Making and Using the Same | MCL1, HPGDS, TPMT | PDE4B 1194/4885PDE4C 1258/4885PDE4A 1112/4885 |
| US-20070244183-A1 | Isoindoline compounds and methods of making and using the same | MCL1, HPGDS, TPMT | PDE4B 1194/4885PDE4C 1258/4885PDE4A 1112/4885 |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4C 5/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.